Johnson & Johnson Subsidiary Janssen Pharmaceuticals Loses Third Risperdal Lawsuit

April 26, 2016 – – LegalHerald.com reports on the third trial loss suffered by Johnson & Johnson subsidiary Janssen Pharmaceuticals when a Philadlphia jury decided on a verdict against them concerning a lawsuit surrounding the atypical antipsychotic drug they manufacture, Risperdal. This trial resulted in an order for Johnson & Johnson to pay $500,000 in compensation to the plaintiff, and was the third loss for the corporate giant, giving hope to many plaintiffs still awaiting their trial dates.

Details of the lawsuit filed indicate that a boy from Wisconsin took the drug and developed gynecomastia while taking it. Gynecomastia is a medical condition which causes males to develop substantial breast tissue mass, causing their breasts to resemble female breasts. As is easily imaginable, the condition causes both physical and emotional turmoil for young boys who are frequently teased and bullied for their breast development.

Additional details surrounding the case show that the jury returned their verdict within just six hours, and found defendant Janssen (Johnson & Johnson) guilty of failing to adequately warn consumers and medical professionals about the risks associated with Risperdal. They also noted that the drug had in fact caused the breast development in the young man.

Unfortunately, this young man is not the only one to have made these claims regarding Risperdal. He is joined by many other plaintiffs from across the U.S. who have filed their own lawsuits discussing the drug and alleging much the same. It was recently reported that more than 1,600 other Risperdal cases are awaiting their day in trial at this time in the Philadelphia, Pennsylvania Court of Common Pleas.

As this lawsuit loss marked the third loss for the defendant and the previous two losses also resulted in substantial monetary awards of $2.5 million and $1.75 million to plaintiffs, many involved have noted that it is plausible that these outcomes may push the defendant to consider settlement negotiations and deals for lawsuits still pending. Individuals close to the lawsuit groups explain that if a jury was able to connect these plaintiffs’ use of Risperdal to their development of gynecomastia, it is increasingly likely that future juries will do the same for the 1,600 other filings.

The attorneys of Banville Law are currently working to assist other patients who have used Risperdal and who feel that it has caused them to suffer from adverse health events. They hope to help ensure that all affected patients are given an opportunity to evaluate their legal rights in the matter, as they may be eligible for significant compensation. To help those wishing to learn more, the attorneys of Banville Law are now offering complimentary legal consultations for qualified parties.

To request further information on Risperdal lawsuits, or to ask questions, contact the attorneys of Banville Law at your convenience by calling 888-997-3792.

###

Contact Banville Law:

Laurence Banville, Esq.
888-997-3792
info@banvillelaw.com
165 West End Avenue, #1H
New York, NY 10023
United States (US)

ReleaseID: 60009614